it is not unusual for growth tech companies with high gross margins to trade at 10x revenue market cap. So assuming 15m AUD revenue over the next 12 months (very conservative if things go well), we should see a 150m MC. 10+ bags (90 cents+). A lot of assumptions to make that assessment including we will need FDA EUA and sufficient capital to deliver demand. Capital should not be a problem once FDA EUA is achieved. The tech is also likely applicable to testing other viruses, simultaneously, providing further upside long term but this is yet to be confirmed. Also a bunch of other irons in the fire with existing revenues.
Anyone who thinks this a pump and dump, I suggest you research our CEO and look at their track record. Impressive is an understatement. You could also model revenue growth, gross margins and overheads to date. It is a very good trajectory. We have been, and remain in, a strong uptrend since the covid opportunity came on the radar earlier this year. Impressive pump if that's what is happening here lol.
Bluechips, ETF's or LIC's might be a better option if you want to satisfy traditional valuation metrics. This is a tech startup and purely a speculative play at this stage. No dividends, no certainty. Anyone who does not know that is an idiot and should *!-: off. You are in the wrong place. Risk/Reward. That is why people are here.
SE1 Price at posting:
9.0¢ Sentiment: Hold Disclosure: Held
